Skip to main content

Table 2 Associations of clinicopathologic variables and disease outcome in ER-positive endocrine-treated breast cancer patients (n = 118) with S100β using Fisher’s exact test. Median age was 51.22 years , median follow-up time was 59.71 months and monitoring blood tests were taken >12 months post-operation (median 24.32 months)

From: S100β as a serum marker in endocrine resistant breast cancer

 

S100β ≥0.13 μg/Ln = 10 (8.47%)

S100β <0.13 μg/Ln = 108 (91.53%)

p value

Age

 ≥55

3 (30%)

64 (59.26%)

0.099

  < 55

7 (70%)

44 (40.74%)

PR

  + ve

8 (80%)

87 (80.56%)

1.00

 –ve

2 (20%)

21 (19.44%)

HER2

  + ve

3 (30%)

52 (51.49%)

0.097

 –ve

7 (70%)

49 (48.51%)

Node

  + ve

2 (22.22%)

43 (47.25%)

0.162

 –ve

7 (77.78%)

48 (52.75%)

Grade

 ≥3

4 (40%)

26 (24.07%)

0.273

 <3

6 (60%)

82 (75.93%)

Size

 ≥20 mm

7 (100%)

81 (96.43%)

1.00

  < 20 mm

3 (3.57%)

Recurrence

  + ve

5 (50%)

17 (15.74%)

0.019

(r = +0.245)

 –ve

5 (50%)

91 (84.26%)